Article Text

Download PDFPDF

Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies
  1. Juichi Fujimori1,
  2. Yoshiki Takai2,
  3. Ichiro Nakashima2,
  4. Douglas Kazutoshi Sato2,
  5. Toshiyuki Takahashi2,3,
  6. Kimihiko Kaneko2,
  7. Shuhei Nishiyama2,
  8. Mika Watanabe4,
  9. Hiroaki Tanji1,
  10. Michiko Kobayashi1,
  11. Tatsuro Misu5,
  12. Masashi Aoki2,
  13. Kazuo Fujihara5
  1. 1 Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
  2. 2 Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
  3. 3 Department of Neurology, Yonezawa National hospital, Yonezawa, Japan
  4. 4 Department of Pathology, Tohoku University Hospital, Sendai, Japan
  5. 5 Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Japan
  1. Correspondence to Dr Juichi Fujimori, Department of Neurology, Tohoku Medical and Pharmaceutical University, 1-12-1 Fukumuro, Miyagino-ku, Sendai 983-8512, Japan; j-fujimori{at}

Statistics from

Encephalitis seldom causes paraparesis as the initial symptom. Here, we report a case of steroid-responsive bilateral frontal cortical encephalitis involving leg motor areas in a patient who presented with paraparesis on admission. Interestingly, the initial paraparesis evolved into an acute disseminated encephalomyelitis (ADEM)-like illness and optic neuritis, and the patient was found to be positive for anti-myelin oligodendrocyte glycoprotein (MOG) antibodies.

Case report

A 46-year-old man experienced transient dizziness in early September 2008. Brain MRI retrospectively showed a slight fluid attenuation inversion recovery (FLAIR) high-intensity lesion involving the left frontal cortex (figure 1). One week later, the patient experienced a focal motor seizure in the right leg that subsequently generalised. Thereafter, he gradually developed headache and paraparesis over the course of a week. On admission, he presented with paraparesis without other neurological deficits, but the spinal MRI was normal. An electroencephalogram revealed that there were no epileptic discharges. A cerebrospinal fluid (CSF) examination revealed elevated leucocytes (56 /µL; 93% mononuclear cells, 3% polymorphonuclear leucocytes) and normal protein (36 mg/dL) and glucose (59 mg/dL) levels. The myelin basic protein (MBP) and glial fibrillary acidic protein levels in the CSF were not elevated. Cell-based assays for anti-N-methyl-D-aspartate receptor (NMDAR) antibodies, anti-voltage-gated potassium channel (VGKC) antibodies, anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antibodies and anti-γ-aminobutyric acid-B receptor (GABA(B)R) antibodies in the CSF were negative. Blood and CSF examinations for infectious central nervous system (CNS) CNS diseases, collagen diseases, vasculitis, Behçet disease, sarcoidosis, lymphoma, paraneoplastic syndrome, vitamin B deficiency and Hashimoto encephalopathy were unremarkable.

Figure 1

Upper panel: axial fluid attenuation inversion recovery (FLAIR) images (1.5 T; TR 6000 ms, TE 105 ms). (A) Brain MRI at the onset revealed a faint high-intensity lesion involving the left frontal cortex, and the lesion appeared normal on diffusion-weighted imaging (DWI). Sagittal T2-weighted images (1.5 T; TR 3210 ms, TE 105 ms) (B) and axial and coronal FLAIR images (C–E). Brain MRI taken 12 days after admission revealed a high-intensity lesion involving the corpus callosum, bilateral cingulate gyrus and medial side of the bilateral frontal lobes, and this lesion appeared as a faint high-intensity area on DWI. Coronal T1-weighted images (1.5 T; TR 470 ms, TE 15 ms) after gadolinium enhancement (F). Brain MRI revealed contrast enhancement in these lesions that diminished after steroid pulse therapy. Axial T2-weighted images (1.5 T; TR 3200 ms, TE 544 ms) (G) just before the brain biopsy showed high-intensity signals involving both cingulate gyri, the corpus callosum and the medial aspect of the bilateral frontal lobes. Axial FLAIR images from November 2008 (H–J) revealed new high-intensity lesions surrounding the third ventricle and aqueduct of the midbrain and in the bilateral thalamus, although the high-intensity lesions involving the corpus callosum, bilateral cingulate gyrus and medial side of the bilateral frontal lobes had been resolved. Axial FLAIR images from January 2009 (K) revealed a new high-intensity lesion in the right basal ganglia. Coronal T1-weighted image (1.5 T; TR 615 ms, TE 15 ms) with gadolinium enhancement from August 2010 (L) revealed the enhancement of the right optic nerve. Middle panel: Paraffin-embedded biopsied brain slices. (M) The tissues were extensively spongy, reflecting brain oedema. Some cerebral vessels (rectangle) were cuffed with inflammatory cells. (H&E stain; 200x.) (N) Myelin sheaths throughout the biopsy samples were densely stained with luxol fast blue, thus indicating no evidence of demyelination (Kluver-Barrera stain; 200x). (O–Q) Perivascular cuffing shown in M. T and B lymphocytes infiltrated around the vessels, whereas macrophages were more diffusely scattered in the brain parenchyma (O, CD3; P, CD20; Q, CD68; 400x). (R) The immunostaining of myelin oligodendrocyte glycoprotein (MOG) also revealed intact myelin sheaths (MOG; 400x). (S) Axons stained for neurofilaments were quite well preserved. Only a few axonal alterations were observed in the sample. Lower panel: Indirect immunofluorescence assay of live human-MOG-transfected cells stained with the serum of the patient. MOG cDNA is expressed on the cell surface. (T) HEK293 cells transfected with MOG were stained with the serum of the patient and fluorescein-conjugated goat anti-human IgG antibody. (U) Bright-field micrograph of the cells. (V) Merge of T and U. The cell surface was stained positive.

After admission, paraparesis progressed gradually, and the patient became completely paraplegic with spasticity 12 days after admission. Furthermore, fever, memory decline and lethargy appeared. iT2-weighted and FLAIR MRI of the brain showed hyperintensities involving the corpus callosum, bilateral cingulate gyri and the medial aspect of the bilateral frontal lobes with contrast enhancement (figure 1B–F). We suspected a certain type of encephalitis, therefore, high-dose intravenous methylprednisolone (1 g for 3 days) and aciclovir (1500 mg/day) were started. His symptoms then improved, and oral prednisolone (PSL) (60 mg/day) was administered beginning in early October 2008. At that time, a CSF examination indicated positive oligoclonal IgG bands, which later became negative in mid-October 2008. CSF-MBP was not elevated at re-evaluation in early October 2008.

Owing to diagnostic uncertainty, a brain biopsy was performed at the right cingulate gyrus in early November 2008. The pathological examination revealed relatively mild tissue damage without demyelinating plaques, neuronal or axonal loss or astrocytic destruction despite the inflammatory and oedematous changes with T-cell and B-cell infiltration. No neoplastic cells were observed (figure 1M–S). Symptomatic improvement was evident, so PSL was tapered to 20 mg/day.

In late November 2008, although the original FLAIR hyperintense area became smaller, new asymptomatic FLAIR hyperintense lesions appeared around the third ventricle and cerebral aqueduct, as well as in the bilateral thalamus and the right nucleus basalis. However, these lesions later spontaneously regressed (figure 1H–K). PSL was tapered to 7 mg/day. In March 2009, the patient could walk without assistance and was discharged. At this time, the original FLAIR high-intensity area had also became markedly smaller.

In late July 2010, PSL was further tapered from 5 mg/day to 4 mg/day. After 1 month, the patient relapsed with right optic neuritis (figure 1L). He had 20/200 vision in his right eye. He was negative for anti-serum aquaporin 4 antibodies. A CSF examination showed normal values of leucocytes (1 /µl; 100% monocytes), protein (29.6 mg/dL) and glucose (55 mg/dL). The patient was treated with steroid therapy, which resulted in a full recovery. Thereafter, administration of PSL (5 mg/day) was continued. His eventual Expanded Disability Status Scale of Kurtzke was 2.0.

In February 2014, our inhouse cell-based assay1 showed that the patient was positive for serum anti-MOG antibodies (figure 1T–V). His antibody titres during the initial episode of encephalitis in mid-October 2008, during his relapse with optic neuritis in late August 2010 and during remission in late February 2014 were 4096x, 4096x and 512x, respectively.


Our case is unique in that the patient with encephalitis involving bilateral frontal cortical areas presented with paraparesis on admission. Common causes of acute and subacute non-traumatic paraplegia are inflammatory, vascular and neoplastic diseases of the thoracic cord, but there have been some rare non-myelopathic causes of paraplegia, such as polyradiculitis, hyperkalemic or hypokalemic paralysis, psychogenic paraplegia and parasagittal cortical syndrome.2 Although bilateral parasagittal cortical syndrome could be observed in cases of bilateral ischaemia in the anterior cerebral artery territories and fast-growing tumours in the parasagittal regions, encephalitis is not usually included in the differential diagnosis of paraplegia.2

The present case was positive for anti-MOG antibodies at the time of the diagnosis of encephalitis, ADEM-like lesions and unilateral optic neuritis. We considered that the anti-MOG antibody was involved in the ADEM-like lesions and optic neuritis in our case, since the clinical course and MRI findings were similar to those of the reported anti-MOG-antibody-positive cases. However, the pathogenetic involvement of anti-MOG antibodies in the unique encephalitis was unclear as neither demyelinating lesions in the brain biopsy nor elevated MBP levels in the CSF previously shown in anti-MOG-antibody-positive patients3 4 were confirmed in the present case. Recently, cases in which anti-NMDAR encephalitis and anti-MOG-antibody-associated demyelinating syndrome coexist have been reported.5 In our case, although no NMDAR, VGKC, AMPAR or GABA(B)R antibodies were detected, autoimmune encephalitis other than autoantibody-mediated encephalitis involving those antibodies might coexist with anti-MOG-antibody-associated demyelinating syndrome. Further study is needed to clarify the expanded spectrum of anti-MOG-antibody-associated diseases.


Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.